Skip to main content

Advertisement

Log in

The presentation of an asymptomatic ovarian carcinosarcoma caught by BRCA1 mutation surveillance program

  • Case report
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

Women with the BRCA1/2 mutations, which cause hereditary breast and ovarian cancer (HBOC), are 35–40 times more likely to develop ovarian cancer compared with the general population. We treated a patient in whom ovarian carcinosarcoma was identified during surveillance for HBOC. She had suffered from breast cancer at ages 45 and 50. At the age of 54 years, she was diagnosed as carrying an “uncertain significant” BRCA1 variant using a genetic mutation analysis. She was referred to our department, and surveillance was performed every 3–6 months for BRCA1 pathogenic mutation carriers due to her family history. At the age of 62 years, cervical and endometrial cytology suggested a diagnosis of adenocarcinoma. At this point, the CA125 level was 19.7 and positron emission tomography/computed tomography (PET/CT) images revealed a right ovarian tumor (SUVmax, 7.41). Surgery was performed, and ovarian carcinosarcoma (pT3cN0M0) was diagnosed. Adjuvant chemotherapy consisting of paclitaxel and carboplatin was initiated. In the month during which the cancer was identified, BRCA1 variant mutation was re-designated as “suspected deleterious,” and 8 years after the initial genetic diagnosis, the causative mutation was identified. The patient has been disease-free for 4 years since surgery. This case demonstrates both the importance and difficulty of surveillance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. (2009) The general rules for clinical and pathological management of ovarian tumors; part 1: histological classification and color atlas of ovarian tumors. Jpn Soc Pathol 19–20

  2. Harris MA, Delap LM, Sengupta PS et al (2003) Carcinosarcoma of the ovary. Br J Cancer 88:654–657

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Silasi DA, Illuzzi JI, Kelly MG et al (2008) Carcinosarcoma of the ovary. Int J Gynecol Cancer 18:22–29

    Article  PubMed  Google Scholar 

  4. Chun KC, Kim JJ, Kim DY et al (2011) Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcoma: a single center experience. Gynecol Obstet Invest 2011:208–214

    Article  Google Scholar 

  5. Sonoda Y, Saigo PE, Federici MG et al (2000) Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin. Gynecol Oncol 76:226–229

    Article  PubMed  CAS  Google Scholar 

  6. Bast RC Jr, Mills GB (2010) Personalizing therapy for ovarian cancer: BRCAness and beyond. JCO 28:3545–3548

    Article  CAS  Google Scholar 

  7. Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71

    Article  PubMed  CAS  Google Scholar 

  8. Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792

    Article  PubMed  CAS  Google Scholar 

  9. Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Bolton KL, Chenevix-Trench G, Goh C et al (2012) Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307:382–390

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Yang D, Khan S, Sun Y et al (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306:1557–1565

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. Gómez García EB, Oosterwijk JC, Timmermans M et al (2009) A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res 11:R8

    Article  PubMed  PubMed Central  Google Scholar 

  13. Finch A, Beiner M, Lubinski J et al (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with BRCA1 or BRCA2 mutation. JAMA 296:185–192

    Article  PubMed  CAS  Google Scholar 

  14. Domchek SM, Friebel TM, Singer CF et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–975

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. (2013) National Cancer Network: NCCN Clinical Practice Guidelines in Oncology Genetic/Familial High-risk Assessment: Breast and Ovarian

  16. Van der Velde NM, Mourits MJ, Arts HJ et al (2009) Time to stop ovarian screening in BRCA1/2 mutation carriers? Int J Cancer 124:919–923

    Article  PubMed  Google Scholar 

  17. Arai A, Taki K, Iwase H et al (2012) Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer (in Japanese). Gan to kagaku ryoho 39:525–531

    PubMed  Google Scholar 

  18. Takeshima N, Teshima H, Minami T et al (1994) The clinical usefulness of the endometrial cytology using Masubuchi’s aspiration tubes in ovarian and fallopian tube cancer (in Japanese). J Jpn Soc Clin Cytol 33:1086–1091

    Article  Google Scholar 

Download references

Acknowledgments

We are grateful to Ms. Ashihara and Ms. Kita Department of Clinical Genetic Oncology, for their constant encouragement and support. We also appreciate the pathological review provided by Dr. Motoyama.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Akiko Abe.

About this article

Cite this article

Abe, A., Sakamoto, K., Taniguchi, T. et al. The presentation of an asymptomatic ovarian carcinosarcoma caught by BRCA1 mutation surveillance program. Int Canc Conf J 3, 242–246 (2014). https://doi.org/10.1007/s13691-014-0155-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13691-014-0155-9

Keywords

Navigation